Natixis Advisors, L.P. Macrogenics Inc Transaction History

Natixis Advisors, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	SELL	$9.77 - $21.47 $65,371 - $143,655	-6,691 Reduced 21.66%	24,201 $356,000
Q4 2023 Feb 06, 2024	BUY	$4.48 - $10.11 $138,396 - $312,318	30,892 New	30,892 $297,000
Q1 2022 May 12, 2022	SELL	$8.12 - $16.9 $118,551 - $246,739	-14,600 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$15.91 - $21.88 $10,691 - $14,703	-672 Reduced 4.4%	14,600 $234,000
Q3 2021 Nov 15, 2021	SELL	$19.74 - $28.7 $12,988 - $18,884	-658 Reduced 4.13%	15,272 $320,000
Q2 2021 Aug 12, 2021	SELL	$20.49 - $35.63 $6,946 - $12,078	-339 Reduced 2.08%	15,930 $428,000
Q1 2021 May 05, 2021	BUY	$18.99 - $33.2 $110,312 - $192,858	5,809 Added 55.54%	16,269 $518,000
Q4 2020 Feb 12, 2021	BUY	$19.41 - $26.0 $203,028 - $271,960	10,460 New	10,460 $239,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.